Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOB versus autologous bone graft for hypotrophic non-union fractures
NL-OMON41222Phase 3Withdrawn
- Sponsor
- BioSenic
- Start
- Mar 2013
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of PREOB in fracture nonunion and pseudoarthrosis (2 arms), sponsored by BioSenic. Primary endpoints: Global disease evaluation and Radiological healing by CT. Planned start Mar 2013; status: withdrawn.
02
Drugs
PREOB
03
Conditions
fracture nonunionpseudoarthrosis
Beyond the preview
Go deeper on NL-OMON41222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41222.